Cardiac Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Systemic amyloidosis encompasses a group of diseases characterized by the deposition of misfolded fibrillar proteins in the extracellular matrix. Over 30 different precursor proteins can undergo substantial molecular transformations to form amyloid fibrils in vivo. Two primary types of amyloid commonly infiltrate the cardiac tissue: immunoglobulin light chain (AL) amyloidosis and transthyretin (ATTR) amyloidosis. In systemic amyloidosis, cardiac involvement is the primary cause of morbidity and mortality, irrespective of the specific mechanism underlying amyloid production. Both light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR) can affect the heart, leading to symptoms such as heart failure, arrhythmias, and other extracardiac manifestations. AL amyloidosis is relatively rare, while ATTR has varying clinical penetrance and is associated with different variants. The pathophysiology involves the extracellular deposition of misfolded protein amyloid fibrils, compromising ventricular compliance and systolic function. Cardiac biomarkers like NT-proBNP and troponins help assess prognosis in these conditions. Additionally, amyloid infiltration of intramyocardial vessels frequently reduces myocardial perfusion. The conduction system is often disrupted, manifesting in atrial arrhythmias (fibrillation, flutter, or atrial tachycardia) and atrioventricular conduction delays. Ventricular arrhythmias may also occur, although sustained ventricular tachycardia is infrequent. Bortezomib, a proteasome inhibitor used alone or typically in combination with other agents, has become the most commonly employed first-line treatment in AL amyloidosis. It is associated with hematological response rates of up to 90%, with 60% of patients achieving complete response or excellent partial response. No specific regimen has been proven superior in high-risk (stage IIIb) patients. Alternative combination regimens may be more suitable for patients with significant peripheral or autonomic neuropathy, considering the potential neurotoxicity of bortezomib, and for those with underlying lymphoplasmacytic lymphoma. High-dose melphalan followed by autologous stem cell transplantation is associated with the most durable remissions. However, careful patient selection is crucial due to the risk of treatment-related mortality, particularly among older and more debilitated patients, including those with advanced cardiac or autonomic nerve involvement.

Thelansis’s “Cardiac Amyloidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cardiac Amyloidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Cardiac Amyloidosis across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Cardiac Amyloidosis Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Cardiac Amyloidosis – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033